Chorea News and Research

RSS
HSG conducts clinical trial with novel drug formulation for treating Huntington disease

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

MID1 complex binds with messenger RNA and controls synthesis of defective Huntingtin

MID1 complex binds with messenger RNA and controls synthesis of defective Huntingtin

TP PCR methodology may help streamline genetic testing for Huntington's

TP PCR methodology may help streamline genetic testing for Huntington's

New AAN guideline recommends several treatments for people with Huntington's chorea

New AAN guideline recommends several treatments for people with Huntington's chorea

Measuring wellbeing in Huntington’s disease

Measuring wellbeing in Huntington’s disease

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

Neurocrine completes NBI-98854 Phase IIa study in schizophrenia patients with dyskinesia

Neurocrine completes NBI-98854 Phase IIa study in schizophrenia patients with dyskinesia

UMMS, Lundbeck announce research collaboration to develop targeted therapy for HD

UMMS, Lundbeck announce research collaboration to develop targeted therapy for HD

UMMS, Lundbeck enter research collaboration to develop targeted therapy for HD

UMMS, Lundbeck enter research collaboration to develop targeted therapy for HD

Scientists discover fundamental mechanism behind toxic protein aggregation in neurodegenerative diseases

Scientists discover fundamental mechanism behind toxic protein aggregation in neurodegenerative diseases

Tel Aviv University research links obsessive-compulsive disorder to common childhood illness

Tel Aviv University research links obsessive-compulsive disorder to common childhood illness

Prevalence of HD substantially underestimated in the UK

Prevalence of HD substantially underestimated in the UK

Accumulation of mutated protein may explain damaging cellular behavior in Huntington's disease

Accumulation of mutated protein may explain damaging cellular behavior in Huntington's disease

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

Presentation of results from open-label extension study of Xenazine

Presentation of results from open-label extension study of Xenazine

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Cedars-Sinai Regenerative Medicine Institute supplies stem cells to aid Huntington's disease research

Cedars-Sinai Regenerative Medicine Institute supplies stem cells to aid Huntington's disease research

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

HDSA honors outstanding contributors against Huntington's Disease

HDSA honors outstanding contributors against Huntington's Disease